Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Daiichi Europe gets rights to Nektar's breast cancer therapy Onzeald

Executive Summary

Nektar Therapeutics granted Daiichi Sankyo Europe GMBH exclusive rights to sell its breast cancer therapy Onzeald (etirinotecan pegol) in Europe, Switzerland, and Turkey.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Royalty or Profit Split Information
    • Marketing-Licensing

Related Companies

Advertisement
UsernamePublicRestriction

Register